Literature DB >> 26929941

Increased pertechnetate and radioiodine uptake in the thyroid gland with subacute thyroiditis and concurrent Graves' disease.

Lanzhen Li1, Lixia Sun, Shuiqing Yu, Chao Ma.   

Abstract

OBJECTIVE: A 61 years old woman presented with low grade fever and weight loss for a month. Thyroid function tests showed hyperthyroidism: increased technetium-99m pertechnetate ((99m)Tc O(-)4) and radioiodine ((131)I) uptake and elevated thyroid stimulating hormone receptor antibodies (TSHRAb). She also had high erythrocyte sedimentation rate. Fine-needle aspiration (FNA) biopsies of left thyroid lobe revealed subacute thyroiditis (SAT). Simultaneous occurrence of SAT and Graves' disease (GD) was diagnosed. The patient was in good physical condition after two doses of betamethasone and daily administration of low dose antithyroid drugs.
CONCLUSION: This case indicated that the measurement of TSHRAb is useful in understanding the clinical course of patients with SAT when thyroid function tests including the (99m)Tc and (131)I uptake are not compatible with the diagnosis. In such cases, GD should be suspected. The mechanism of high (99m)Tc and/or (131)I uptake in patients with simultaneous SAT and GD may be due to the inflammatory process which was detected by FNA in a small part of the left thyroid lobe inducing the stimulating effects of elevated TSHRAb on the undamaged follicular cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26929941     DOI: 10.1967/s002449910338

Source DB:  PubMed          Journal:  Hell J Nucl Med        ISSN: 1790-5427            Impact factor:   1.102


  2 in total

1.  A Case of Thyrotoxicosis due to Simultaneous Occurrence of Subacute Thyroiditis and Graves' Disease.

Authors:  Kazunori Kageyama; Noriko Kinoshita; Makoto Daimon
Journal:  Case Rep Endocrinol       Date:  2018-10-30

2.  Establishing a diagnostic scale of subacute thyroiditis without radioisotope scanning.

Authors:  Zhouyi Xiong; Chunying Luo; Li Wang; Bin Xiong; Jianneng Wu
Journal:  BMC Endocr Disord       Date:  2020-05-27       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.